about
Total and functional parasite specific IgE responses in Plasmodium falciparum-infected patients exhibiting different clinical statusPrevalence of Plasmodium falciparum infection in pregnant women in GabonSevere falciparum malaria in Gabonese children: clinical and laboratory featuresIntramuscular Artesunate for Severe Malaria in African Children: A Multicenter Randomized Controlled TrialNew highly divergent rRNA sequence among biodiverse genotypes of Enterocytozoon bieneusi strains isolated from humans in Gabon and Cameroon.Self-reactivities to the non-erythroid alpha spectrin correlate with cerebral malaria in Gabonese children.Complicated malaria and other severe febrile illness in a pediatric ward in Libreville, Gabon.Evidence of decline of malaria in the general hospital of Libreville, Gabon from 2000 to 2008Falciparum malaria as an emerging cause of fever in adults living in Gabon, Central Africa.Burden of malaria during pregnancy at the time of IPTp/SP implementation in Gabon.Short-course regimens of artesunate-fosmidomycin in treatment of uncomplicated Plasmodium falciparum malaria.Intramuscular bioavailability and clinical efficacy of artesunate in gabonese children with severe malaria.Malaria transmission and insecticide resistance of Anopheles gambiae in Libreville and Port-Gentil, Gabon.Sub-microscopic gametocyte carriage in febrile children living in different areas of Gabon.Multinormal in vitro distribution model suitable for the distribution of Plasmodium falciparum chemosusceptibility to doxycycline.Mortality patterns and site heterogeneity of severe malaria in African children.Asymptomatic Plasmodium falciparum infection in children is associated with increased auto-antibody production, high IL-10 plasma levels and antibodies to merozoite surface protein 3.Malaria transmission in Libreville: results of a one year survey.Sulphadoxine/pyrimethamine versus amodiaquine for treating uncomplicated childhood malaria in Gabon: a randomized trial to guide national policy.Increase in malaria prevalence and age of at risk population in different areas of Gabon.Antenatal care visit attendance, intermittent preventive treatment and bed net use during pregnancy in Gabon.Prognostic value of circulating pigmented cells in African children with malariaCercarial emergence pattern of Schistosoma haematobium from Libreville, Gabon.Phase 2a, Open-Label, 4-Escalating-Dose, Randomized Multicenter Study Evaluating the Safety and Activity of Ferroquine (SSR97193) Plus Artesunate, versus Amodiaquine Plus Artesunate, in African Adult Men with Uncomplicated Plasmodium falciparum MalaIncreased prevalence of intestinal helminth infection during pregnancy in a Sub-Saharan African community.Efficacy and safety of a new pediatric artesunate-mefloquine drug formulation for the treatment of uncomplicated falciparum malaria in Gabon.High prevalence of sulfadoxine/pyrimethamine-resistant alleles of Plasmodium falciparum isolates in pregnant women at the time of introduction of intermittent preventive treatment with sulfadoxine/pyrimethamine in Gabon.Impact of Plasmodium falciparum infection on the frequency of moderate to severe anaemia in children below 10 years of age in Gabon.Differential var gene expression in children with malaria and antidromic effects on host gene expression.Reduced CD3/TCR complex expression leads to immunosuppression during Plasmodium falciparum malaria.Morbidity and mortality of wild animals in relation to outbreaks of Ebola haemorrhagic fever in Gabon, 1994-2003.Immunoblot analysis of membrane antigens of Schistosoma mansoni, Schistosoma intercalatum, and Schistosoma haematobium against Schistosoma-infected patient sera.Evaluation of rapid diagnostic tests for malaria case management in Gabon.Epilepsy as a consequence of cerebral malaria in area in which malaria is endemic in Mali, West Africa.Cerebral malaria and sequelar epilepsy: first matched case-control study in Gabon.Prenatal immune responses to Plasmodium falciparum erythrocyte membrane protein 1 DBL-alpha domain in Gabon.Malaria in pregnancy before and after the implementation of a national IPTp program in Gabon.Differences in presentation of severe malaria in urban and rural Gabon.Ferroquine and artesunate in African adults and children with Plasmodium falciparum malaria: a phase 2, multicentre, randomised, double-blind, dose-ranging, non-inferiority study.Anaemia and severe malarial anaemia burden in febrile Gabonese children: a nine-year health facility based survey.
P50
Q21033441-72208429-B42F-4484-91A6-F6E7DFE46B3EQ24794494-76CEC447-E827-42E8-82DF-6332BBA1AA71Q24795463-48F53A63-6BA2-4201-AF87-A1342DDD97F0Q28552379-25FEBD8D-711A-43BF-8BE8-B81618056456Q30362024-3F7DB399-17B6-4BD1-95B7-0233C8E9E760Q33282860-F6E4DB52-AAD8-4ECF-B34B-1CAE4C1474B5Q33403284-B2A85F18-A708-4E5C-9BD3-6C9C6D87A065Q33590182-D73A6166-F426-4625-8D01-008D57F0D822Q33616091-11BC8B26-2E6D-4198-A1C7-93521B38D9E5Q33617540-A16D0C1C-3215-4D5B-B183-149ADBB23DD5Q33935493-D666A030-6ECD-4FB9-8DFF-14E37B377597Q34252476-93303E1D-8365-4FB8-AB31-8FCB94CE5E3DQ34372461-A5BEB383-5FF5-4E2B-BCE6-55B913AB2A26Q34493765-73F87F0E-8D7C-4C66-82EC-E9D494EAE11BQ34601191-4C4C44F4-2C7D-481D-BD0E-80933B3926A4Q34625988-71E60C85-4775-408F-8EC1-67E75E8FB462Q35568907-92243809-2746-4061-89F2-E4DF1954C061Q35848028-453A1BFF-9FD1-4429-979E-9144B9AA8069Q36512560-87A6D08E-765D-487C-A30F-0CF382B87A45Q36547824-D88249C1-EFD7-4B42-8913-406CC845B891Q36690150-F92D7187-26CA-4CE9-931C-B730B1F069F5Q37127577-D865E90B-2042-4F0B-A115-FCF9E583ED12Q37566084-7D64BE64-D52E-45E0-95DE-5CA738D8ED7DQ38655307-9774627C-4F05-4FFD-94AA-B5879DEBD653Q38860337-FE527A5F-505F-4055-8D18-521B28C09220Q38918039-736803E0-655D-44E2-8023-CD00B19141FFQ38918045-14B5074B-92BD-450E-AA10-F3D117BC1362Q38918052-B6BE4ED3-21F5-4490-BDFE-B7FCD257D15EQ39116665-0A0E4CFE-3749-417B-8101-111722EBFADBQ39116671-3124832C-47FD-48F4-953C-BABE4C0830A1Q39156887-A6806F82-0D4E-49B3-8DA9-BBD9C3353534Q39195976-74816AC7-4088-4E76-96C5-0656F54C64F8Q39227718-288F8D06-9C57-4A96-900F-4C4BE8AA7DEFQ39301817-415B1A3F-3803-4247-8DEB-767673D43354Q39301826-DCB8DF6F-4A25-4B4A-AFA2-0B04A477810AQ39517036-5B4C7A88-C4E8-4C2F-B8BF-328A63B86C19Q39812394-3CB095D2-5325-4711-8104-B0631B315E47Q39827451-8B62FBF4-1E19-4DCD-8281-F4D05F9F73AEQ40140463-A127C6B0-7ABA-401E-A945-08790B2D0F62Q40225081-02B4B933-279B-440D-A8B4-CD60BBF204EC
P50
name
Maryvonne Kombila
@en
type
label
Maryvonne Kombila
@en
prefLabel
Maryvonne Kombila
@en